Vatalanib (hydro<wbr>chloride)

Vatalanib (hydrochloride)

CAT N°: 14868
Price:

From 77.00 65.45

Vatalanib is an antagonist of the VEGF receptors, inhibiting the receptor tyrosine kinase activities of VEGFR1 (Flt1), VEGFR2 (KDR), and VEGFR3 (Flt4) with IC50 values of 77, 37, and 190 nM, respectively.{24346,24345} It less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on a large panel of additional kinases.{24346,24344,24345} Vatalanib completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice, suggesting its use in diabetic retinopathy and other diseases featuring aberrant vascular development.{18281,24343}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, dihydrochloride
  • Correlated keywords
    • inhibitors inhibits inhibitions receptors antagonists cancers angiogenesis diabetes proteins kinases signals transduction angiogenesis potent selective VEGFs tyrosine VEGFRs VEGFR1 VEGFR-1 1 one VEGFR2 VEGFR-2 2 two VEGFR3 VEGFR-3 3 three Flt1 Flt-1 Flts KDRs Flt-4 Flt4 four 4 retinal neovascularization retinopathy aberrant vascular CGPs 79787 CGP-79787 CGP79787 ZKs 222584 ZK-222584 ZK222584 PTKs PTK-787 PTK787 PTKZK PTK/ZK ZK 212141-54-3
  • Product Overview:
    Vatalanib is an antagonist of the VEGF receptors, inhibiting the receptor tyrosine kinase activities of VEGFR1 (Flt1), VEGFR2 (KDR), and VEGFR3 (Flt4) with IC50 values of 77, 37, and 190 nM, respectively.{24346,24345} It less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on a large panel of additional kinases.{24346,24344,24345} Vatalanib completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice, suggesting its use in diabetic retinopathy and other diseases featuring aberrant vascular development.{18281,24343}

We also advise you